Novo Nordisk secures FDA approval of RNAi therapy from $3.3B Dicerna takeover
Two years later, Novo Nordisk’s $3.3 billion buyout of Dicerna Pharmaceuticals’ RNAi platform is beginning to pay off.
Novo scored an approval on Monday for nedosiran, an RNAi therapy developed by Dicerna to treat a rare kidney disease called primary hyperoxaluria type 1 (PH1). The drug, marketed as Rivfloza, is expected to be available in early 2024, Novo said in an announcement.
PH is a genetic disease marked by an excessive production of oxalate, a substance that can combine with calcium to cause kidney stones. Some patients may need dialysis, while continued oxalate buildup can also damage other organs. Rivfloza is approved to lower urinary oxalate levels in adults and children 9 years and older.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
